ARQT — Arcutis Biotherapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1787306 ·
Last close
$27.33
Market Cap
$3.46B
52W High
$34.80
52W Low
$19.30
ADV30
2,397,328
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 143,919,000 131,459,000 9,436,000 8,801,000 524,426,000 33,373,000 280,460,000
Jun 2026 129,861,000 118,922,000 16,429,000 15,009,000 488,537,000 34,121,000 267,958,000
Mar 2026 105,398,000 95,614,000 -9,089,000 -11,295,000 460,003,000 34,762,000 270,355,000
Dec 2025 129,503,000 117,815,000 18,387,000 17,395,000 432,973,000 42,907,000 243,494,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$59,961,000
Investing CF
$-82,819,000
Financing CF
$9,232,000
CapEx
$-10,783,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.21
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,125,569,000
Inventory
$45,669,000
Receivables
$171,281,000
ST Investments
$226,087,000
EBIT TTM
$44,538,000
Pretax Income TTM
$30,804,000
Interest Exp TTM
$13,734,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$508,680,992
EBITDA
$37,413,000
Free Cash Flow
$32,623,124
Enterprise Value
$3,095,286,016
Total Cash
$259,460,000
Total Debt
$123,820,000
Shares Out
126,455,033
Trailing EPS
$0.22
Book Value
$1.94
ROE
14.9%
ROA
4.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 376,072,000 -12,227,000 -16,141,000 432,973,000 243,494,000 189,479,000 -5,625,000
Dec 2024 196,542,000 -128,397,000 -140,039,000 348,889,000 191,348,000 157,541,000 -112,158,000
Dec 2023 59,606,000 -241,101,000 -262,140,000 341,365,000 252,698,000 88,667,000 -247,057,000
Dec 2022 3,686,000 -301,627,000 -311,458,000 449,274,000 239,693,000 209,581,000 -257,715,000

TTM Snapshot

Revenues TTM
$463,981,000
NetIncome TTM
$28,519,000
OpCashFlow TTM
—
Assets (Latest)
$488,537,000
Forward EPS
$1.34

Max Pain — expiry 2027-01-15

max pain strike: $15.00 · spot: $27.61 · call oi: 3,999 · put oi: 261
Expected Move to 2027-01-15: ±$5.58 (20.19%) — implied range $22.04 – $33.19 · ATM straddle on $27.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —
VKTX Viking Therapeutics, Inc. $3.43B $26.88 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —
VRDN Viridian Therapeutics, Inc.\DE $3.41B $30.06 —

News headlines (Yahoo Finance, 1h cache)

Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
2026-11-14 01:16 · Yahoo
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Mee
2026-11-13 14:00 · Yahoo
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
2026-11-07 23:08 · Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:00 · Yahoo
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
2026-11-06 10:14 · Yahoo
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
2026-11-05 21:22 · Yahoo
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
2026-11-05 13:00 · Yahoo
Arcutis Biotherapeutics Q3 Earnings Call Highlights
2026-11-05 00:14 · Yahoo
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
2026-11-04 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.